Food Intake and Epigenetic Alteration in the Spermatozoa of Singletons and Twins (FEASST)

December 6, 2023 updated by: University of Copenhagen

The FEASST Study: Food Intake and Epigenetic Alteration in the Spermatozoa of Singletons and Twins

The purpose of this study is to elucidate the role of acute dietary intake in male populations, and its impact on spermatozoa quality, integrity, content and epigenetic programming.

Study Overview

Detailed Description

The FEASST study has been designed to determine the impact of diet on the content, quality, and genetic programming of sperm. They are specifically interested in determining if a man's diet plays a role in influencing the health of his potential, future offspring through modifications of the sperm. Previous research has highlighted that certain dietary patterns in fathers-to-be may lead to variable health outcome for their children. However, the specific effect of a man's diet has yet to be fully understood. This study will help understand the impact of a man's diet on semen quality and potential downstream implications for child health, to aid in the development of dietary guidelines for future fathers-to-be.

For this study, male participants will be provided with two prescribed diets for three-week increments punctuated by a three month break. Health information and biological samples such as blood, semen, and saliva will be collected from study participants throughout the five month period. The diets will consist of a 'Processed diet', mimicking a traditional Western dietary intake pattern and an 'Unprocessed diet', based upon current dietary guidelines at quantities either adequate for the participants energetic needs or 500 calories in excess per day.

Patient information and samples will be collected before and after each dietary intervention. Aspects of patient health examined at various time points include weight, body fat percentage, sperm quality, epigenetic sequencing, serum levels of metabolic parameters, and survey information surrounding health history, typical diet, physical activity patterns, and treatment adherence.

Study Type

Interventional

Enrollment (Actual)

43

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Copenhagen, Denmark, 2200
        • University of Copenhagen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Male
  • 20 to 35 years old
  • BMI 18.5 to 30
  • Located within the Copenhagen region
  • Fluent in English and/or Danish language
  • Sperm concentration of >15 mil/mL according to the WHO's criteria for semen quality
  • Semen volume of >1.5mL mL according to the WHO's criteria for semen quality
  • Clinician approval for participation in study
  • Obtained informed consent

Exclusion Criteria:

  • Self-reported history of serious or chronic illness
  • Self-reported history of Obesity
  • History of any food restrictions
  • History of allergies to any food products
  • History of disordered eating
  • Record of current use of drugs, alcohol (>14 units per week and/or chronic binge drinking), and/or tobacco/nicotine products within the past month
  • Current use of prescription medication
  • Engage in > 200 minutes of vigorous aerobic exercise per week
  • Currently actively trying to conceive a child
  • Diagnosis of infertility or disease of the reproductive system
  • Evidence of dysregulated metabolism, characterized by the occurrence of any one of the following:

    • Waist circumference >102 cm
    • Blood pressure > 130/85 mm Hg

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Isocaloric Arm
Participants within the isocaloric arm will be provided with food provisions in accordance with their nutrition needs. Participants within this arm will be further randomised to the order of first and second dietary interventions for the crossover design; unprocessed diet or processed diet.
Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
Experimental: Excess Calorie Arm
Participants within the excess calorie arm will be provided with food provisions in accordance with their nutrition needs plus an additional 500 kilocalories per day. Participants within this arm will be further randomised to the order of first and second dietary interventions for the crossover design; unprocessed diet or processed diet.
Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Spermatozoa DNA Methylation via Reduced Representation Bisulfite Sequencing
Time Frame: 3 weeks
Differential methylation of CpG sites within mature spermatozoa determined from extracted genomic DNA which has undergone library preperation with Ovation® RRBS Methyl-Seq (NuGEN Technologies) and sequenced on a NextSeq Illumina platform.
3 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sperm Concentration
Time Frame: 3 weeks
Measured in million sperm per mL using LensHooke X1 Pro Semen Quality Analyser and Microscopy-based methodology
3 weeks
Semen Volume
Time Frame: 3 weeks
Measured in mL assuming the density of semen to be 1 g/ml
3 weeks
Sperm Motility
Time Frame: 3 weeks
Measured in precent of sperm classified as progressively motile and non-progressively motile using LensHooke X1 Pro Semen Quality Analyser and Microscopy-based methodology
3 weeks
Spermatozoa smallRNA expression via sequencing of total smallRNA species
Time Frame: 3 weeks
Differential expression of small RNA species within mature spermatozoa performed by generation of RNA sequencing libraries using NEXTFLEX® Small RNA-Seq Kit for Illumina (PerkinElmer), according to the manufacturer's instructions, and sequenced on a NextSeq Illumina platform.
3 weeks
Weight
Time Frame: 3 weeks
Measured in kilograms using a scale (Tanita DC 430 SMA)
3 weeks
Body Mass Index (BMI)
Time Frame: 3 weeks
Calculated based on height and weight measurement using the equation BMI=kg/m^2
3 weeks
Waist Circumference
Time Frame: 3 weeks
Measured in centimetres using a flexible measuring tape (SECA Measuring Tape 201 cm)
3 weeks
Hip Circumference
Time Frame: 3 weeks
Measured in centimetres using a flexible measuring tape (SECA Measuring Tape 201 cm)
3 weeks
Body Fat Precentage
Time Frame: 3 weeks
Measured using DEXA Scanner and Software (GE Lunar Prodigy)
3 weeks
C-reactive protein (CRP)
Time Frame: 3 weeks
Measured in milligrams per litre in serum
3 weeks
Lipoproteins
Time Frame: 3 weeks
Measuring high density lipoproteins and low density lipoproteins in milligrams per litre in plasma
3 weeks
Total protein
Time Frame: 3 weeks
Measured in grams per litre in serum
3 weeks
Testosterone
Time Frame: 3 weeks
Measured in nanograms per deciliter in plasma
3 weeks
Follicle stimulating hormone (FSH)
Time Frame: 3 weeks
Measured in international units per milliliter in serum
3 weeks
Luteinizing hormone (LH)
Time Frame: 3 weeks
Measured in international units per liters in plasma
3 weeks
Progesterone
Time Frame: 3 weeks
Measured in nanograms per milliliter in serum
3 weeks
Estradiol
Time Frame: 3 weeks
Measured in picograms per milliliter in serum
3 weeks
Oestradiol
Time Frame: 3 weeks
Measured in picograms per milliliter in serum
3 weeks
Fasting Blood Glucose
Time Frame: 3 weeks
Measured in whole blood using a handheld glucometer and test strip (Contour next Blood Glucose Meter and Blood Sugar Test strip)
3 weeks
Insulin
Time Frame: 3 weeks
Measured in microunits per milliliter in serum
3 weeks
Haemoglobin A1c (HbA1c)
Time Frame: 3 weeks
Measured in mmol/mol in plasma
3 weeks
Blood pressure
Time Frame: 3 weeks
Systolic and Diastolic blood pressure measured in mmHg using an automatic blood pressure cuff (Omron M6 Comfort Automatic Upper Arm Blood Pressure Monitor, 22-42cm)
3 weeks
Leptin
Time Frame: 3 weeks
Measured in ng/mL in plasma
3 weeks
Glucagon-like peptide 1 (GLP-1)
Time Frame: 3 weeks
Measured in pmol/L in plasma
3 weeks
Gastric inhibitory peptide (GIP)
Time Frame: 3 weeks
Measured in pg/mL in serum
3 weeks
Glucagon
Time Frame: 3 weeks
Measured in pg/mL in serum
3 weeks
Ghrelin
Time Frame: 3 weeks
Measured in pg/mL in plasma
3 weeks
Fibroblast growth factor 21 (FGF-21)
Time Frame: 3 weeks
Measured in pg/ml in serum
3 weeks
Peripheral blood mononuclear cell (PBMC) DNA methylation via Reduced Representation Bisulfite Sequencing
Time Frame: 3 weeks
Differential methylation of CpG sites within PBMCs determined from extracted genomic DNA which has undergone library preperation with Ovation® RRBS Methyl-Seq (NuGEN Technologies) and sequenced on a NextSeq Illumina platform.
3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Romain Barrès, PhD, University of Copenhagen Novo Nordisk Foundation Center for Basic Metabolic Research

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 20, 2021

Primary Completion (Actual)

July 1, 2022

Study Completion (Actual)

July 1, 2022

Study Registration Dates

First Submitted

December 16, 2021

First Submitted That Met QC Criteria

May 9, 2022

First Posted (Actual)

May 10, 2022

Study Record Updates

Last Update Posted (Actual)

December 13, 2023

Last Update Submitted That Met QC Criteria

December 6, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • H-20061598

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Overnutrition

Clinical Trials on Isocaloric Unprocessed Diet

Subscribe